Drug companies aren’t making new antibiotics. Is there an economic cure?

As drug-resistant infections proliferate, financial barriers are preventing the pharmaceutical industry from investing in new drugs to fight off superbugs. Economics correspondent Paul Solman, in a series of reports with science correspondent Miles O'Brien, explores how researchers could be incentivized to develop new antibiotics.


(Source: PBS NewsHour, https://www.youtube.com/watch?v=YU5mPUF99BE)